Mass Cytometry: A Revolutionary Technology for High-Dimensional Single-Cell Analysis
Polaris Biology
Supplier of Single-Cell Precision Diagnosis Technology R&D and Clinical Applications
Our understanding of the human body as a complex system at the molecular level has ushered us into the era of precision medicine. The diagnostic and therapeutic demands for complex diseases such as cancer have further driven us toward networked, multidimensional analysis. The clinical demand for detection technologies is not merely for “higher resolution,” but more importantly, for the ability to “measure more parameters simultaneously and faster.” Among the new generation of high-throughput, multidimensional single-cell detection technologies, mass cytometry stands out as the most representative example. VCBeat contacted Polaris Biology, which provides complete solutions for mass cytometry, and engaged in an in-depth discussion with Dr. Shuangwu Sun, Head of R&D, on why this technology has garnered significant attention.
Q: Could you briefly introduce us to mass cytometry technology?
Dr. Shuangwu Sun:Mass Cytometry is an emerging foundational single-cell analysis technology that combines the primary advantages of Flow Cytometry and Mass Spectrometry. By utilizing antibodies or probes labeled with heavy metal isotopes, it enables the detection and analysis of multiple biomarkers at the single-cell level, offering unprecedented throughput and data dimensionality.
Q: What is the significance of increasing throughput and dimensionality?
Dr. Shuangwu Sun:Quantitative improvements in the detection and analysis of biomarkers will lead to qualitative leaps, and the resulting high-dimensional data can help usA Systemic Understanding of the Interaction Between Tumors and the Immune System Drives a Paradigm Shift in Clinical Treatment.
During drug clinical trials, the single-cell multiparametric analysis capability of mass cytometry can support pharmaceutical companies in conducting refined assessments of patients’ tumor cells and immune systems, thereby enabling stratified management, earlier identification of biomarkers for patient populations likely to benefit, and helping pharmaceutical companies stand out in a highly homogeneous competitive landscape.
In terms of prognostic assessment, the clinical community can leverage the rapid data generation and analysis capabilities of high-dimensional mass cytometry to conduct timely dynamic evaluations of tumors and the immune system during patient treatment, thereby enabling early detection of adverse reactions. Furthermore, the multiplexed detection capability of mass cytometry helps reduce sample volume requirements, making it more suitable for clinical applications.
Finally, with the rapid development of personalized medicine, mass cytometry for diagnosis can inversely drive clinical treatment, helping major pharmaceutical companies develop more precise and efficient innovative therapies. For example, mass cytometry technology can be used for functional screening of tumor neoantigens, performing in vitro biological validation based on predictions from machine learning algorithms to improve treatment efficacy.
Q: To achieve these qualitative leaps, what technological improvements and innovations has Polaris Biology implemented?
Dr. Shuangwu Sun:It mainly involves three aspects. To achieve finer measurements, we improved the sample introduction system of mass cytometry, enablingNearly 100% Sample Injection Efficiency, thereby enabling the analysis of rare cell subsets within the immune system.
Additionally, Polaris Biology's solution also adopts a uniqueBarcodingtechnology, significantly increasing the throughput of sample detection. For example, by arbitrarily selecting three elements from a pool of six to label samples, simultaneous detection of 20 samples can be achieved.
Furthermore, we have developed methods for mass cytometry dataVisualization Analysis Tool, leveraging the characteristic that no "compensation" is required between detection channels, it integrates multiple data analysis algorithms to enable "foolproof" data analysis. The entire workflow, from batch sample processing to batch result reporting, can be completed within 3 hours.
According to Dr. Sun, Polaris Biology has established a full industry chain spanning from upstream equipment and reagent production to downstream diagnostic service development, enabling the company to provide mass cytometry testing solutions with superior performance and accessibility for healthcare institutions and biopharmaceutical companies. Currently, Polaris Biology is collaborating with multiple partners to advance the clinical application of mass cytometry in areas such as hematologic disorders, tumor immunology, and neoantigens.
For clinical applications, the accessibility and affordability of innovative technologies must be balanced to avoid placing an excessive burden on medical insurance systems and patients. To make mass cytometry technology accessible to a broader user base, Polaris Biology’s mass cytometry detection solution, built on independent R&D and comprehensive localization in China, is highly cost-effective, with expected pricing comparable to that of conventional flow cytometry.
The global healthcare industry is undergoing a period of rapid change and growth, with diagnosis and treatment increasingly converging. The efficacy of many novel therapies depends on the depth, breadth, and accuracy of individual patient data collection, driving the entire sector toward an information-centric model. Polaris Biology will further strengthen in-depth collaborations with upstream and downstream enterprises and clinical institutions, continuing to explore the potential applications of mass cytometry technology in broader clinical areas.